Folic acid mitigated cardiac dysfunction by normalizing the levels of tissue inhibitor of metalloproteinase and homocysteine-metabolizing enzymes postmyocardial infarction in mice

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 299, Issue 5, 2010, Pages

  Qipshidze, Natia ^a   Tyagi, Neetu ^a   Sen, Utpal ^a   Givvimani, Srikanth ^a   Metreveli, Naira ^a   Lominadze, David ^a   Tyagi, Suresh C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Ejection fraction; Fractional shortening; Myocyte contractility

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); COLLAGEN; CYSTATHIONINE BETA SYNTHASE; CYSTATHIONINE GAMMA LYASE; FOLIC ACID; GELATINASE A; GELATINASE B; HOMOCYSTEINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

AMINO ACID METABOLISM; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG MECHANISM; ECHOCARDIOGRAPHY; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDSYSTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE CONTRACTILITY; HEART MUSCLE INJURY; HEART RATE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; DIETARY SUPPLEMENTS; FOLIC ACID; HEART; HEMATINICS; HOMOCYSTEINE; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PHYSIOLOGIC; TISSUE INHIBITOR OF METALLOPROTEINASES; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 78249277175     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00577.2010     Document Type: Article

References (52)

1. Antoniades C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, Leeson P, Neubauer S, Ratnatunga C, Pillai R, Refsum H, Channon KM. 5- Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 114: 1193-1201, 2006. (Pubitemid 44386484)
2. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 101: 1478-1487, 1998.
3. Boushey. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 274: 1049-1057, 1995.
4. Butler GS, Apte SS, Willenbrock F, Murphy G. Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B. J Biol Chem 274: 10846-10851, 1999. (Pubitemid 129528287)
5. Carnicer RA, Navarro M, Arbonés-Mainar JM, Acín S, Guzmán MA, Surra JC, Arnal C, de las Heras M, Blanco-Vaca F, Osada J. Folic acid supplementation delays atherosclerotic lesion development in apoE-deficient mice. Life Sci 80: 638-643, 2007.
6. Chao WH, Reynolds RD. Taurine-deficient diet up-regulated cystathionine β-synthase monoallele in hemizygous cystathionine β-synthase knockout mice. Nutr Res 29: 794-801, 2009.
7. Doshi SN, McDowell IFW, Moat SJ, Lang D, Newcombe RG, Kredan MB, Lewis MJ, Goodfellow J. Folate improves endothelial function in coronary artery disease: an effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol 21: 1196-1202, 2001.
8. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106: 55-62, 2000.
9. Eikelboom JWM, Lonn EC, Genest J, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 131: 363-375, 1999.
10. Emi Nakano JAH, Hilary Powers J. Folate protects against oxidative modification of human LDL. Br J Nutr 86: 637-633, 2001.
11. Finkelstein JDMJ. Inactivation of betaine-homocysteine methyltransferase by adenosylmethionine and adenosylethionine. Biochem Biophys Res Commun 118: 14-19, 1984.
12. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94: 2493-2503, 1994.
13. Givvimani S, Tyagi N, Sen U, Mishra PK, Qipshidze N, Munjal C, Vacek JC, Abe OA, Tyagi SC. MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch Physiol Biochem 116: 63-72, 2010.
14. Hautvast JGBM. Collagen metabolism in folic acid deficiency. Br J Nutr 32: 457-469, 1974.
15. Hayashidani STH, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T, Imanaka-Yoshida K, Itoh T, Takeshita A. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 285: H1229-H1235, 2003.
16. Hirayama A, Adachi T, Asada S, Mishima M, Nanto S, Kusuoka H, Yamamoto K, Matsumura Y, Hori M, Inoue M. Late reperfusion for acute myocardial infarction limits the dilatation of left ventricle without the reduction of infarct size. Circulation 88: 2565-2574, 1993.
17. House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, Dresser GK, Spence JD. Effect of B-vitamin therapy on progression of diabetic nephropathy. J Am Med Assoc 303: 1603-1609, 2010.
18. Huang L, Song XM, Zhu WL, Li Y. Plasma homocysteine and gene polymorphisms associated with the risk of hyperlipidemia in Northern Chinese subjects. Biomed Environ Sci 21: 514-520, 2008.
19. Hutchins GM, Bulkley BH. Infarct expansion versus extension: two different complications of acute myocardial infarction. Am J Cardiol 41: 1127-1132, 1978.
20. Kam S, Woo MDF, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia J Am Coll Cardiology 34: 2002-2006, 1999.
21. Kandalam V, Basu R, Abraham T, Wang X, Soloway PD, Jaworski DM, Oudit GY, Kassiri Z. TIMP2 deficiency accelerates adverse postmyocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ Res Mar 106: 796-808, 2010.
22. Kluijtmans LAJ, Boers GHJ, Verbruggen B, Trijbels FJM, Novakova IRO, Blom HJ. Homozygous cystathionine beta-synthase deficiency, combined with factor V leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosis. Blood 91: 2015-2018, 1998.
23. Kumar D, Jugdutt BI. Apoptosis and oxidants in the heart. J Lab Clin Med 142: 288-297, 2003.
24. Kumar M, Tyagi N, Moshal KS, Sen U, Kundu S, Mishra PK, Givvimani S, Tyagi SC. Homocysteine decreases blood flow to the brain due to vascular resistance in carotid artery. Neurochem Int 53: 214-219, 2008.
25. Kumar M, Tyagi N, Moshal KS, Sen U, Pushpakumar SB, Vacek T, Lominadze D, Tyagi SC. GABAA receptor agonist mitigates Hcy-induced cerebrovascular remodeling in knockout mice. Brain Res 1221: 147-153, 2008.
26. Lamberts RR, Caldenhoven E, Lansink M, Witte G, Vaessen RJ, St Cyr JA, Stienen GJM. Preservation of diastolic function in monocrotaline-induced right ventricular hypertrophy in rats. Am J Physiol Heart Circ Physiol 293: H1869-H1876, 2007.
27. Lentz SR. Homocysteine and vascular dysfunction. Life Sci 61: 1205-1215, 1997.
28. Lentz SR, Erger RA, Dayal S, Maeda N, Malinow MR, Heistad DD, Faraci FM. Folate dependence of hyperhomocysteinemia and vascular dysfunction in cystathionine β-synthase-deficient mice. Am J Physiol Heart Circ Physiol 279: H970-H975, 2000.
29. Lominadze D, Schuschke DA, Joshua IG, Dean WL. Increased ability of erythrocytes to aggregate in spontaneously hypertensive rats. Clin Exp Hypertens 24: 397-406, 2002.
30. Lovelock JD, Baker AH, Gao F, Dong JF, Bergeron AL, McPheat W, Sivasubramanian N, Mann DL. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol 288: H461-H468, 2005.
31. Matsusaka H, Ikeuchi M, Matsushima S, Ide T, Kubota T, Feldman AM, Takeshita A, Sunagawa K, Tsutsui H. Selective disruption of MMP-2 gene exacerbates myocardial inflammation and dysfunction in mice with cytokine-induced cardiomyopathy. Am J Physiol Heart Circ Physiol 289: H1858-H1864, 2005.
32. Miller A, Mujumdar V, Palmer L, Bower JD, Tyagi SC. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens 15: 157-163, 2002.
33. Moat SJ, Lang D, McDowell IF, Clarke ZL, Madhavan AK, Lewis MJ, Goodfellow J. Folate, homocysteine, endothelial function and cardiovascular disease. J Nutr Biochem 15: 64-79, 2004.
34. Moens AL, Champion HC, Claeys MJ, Tavazzi B, Kaminski PM, Wolin MS, Borgonjon DJ, Van Nassauw L, Haile A, Zviman M, Bedja D, Wuyts FL, Elsaesser RS, Cos P, Gabrielson KL, Lazzarino G, Paolocci N, Timmermans JP, Vrints CJ, Kass DA. High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation 117: 1810-1819, 2008.
35. Moshal KS, Tipparaju S, Kumar M, Tyagi N, Metreveli N, Frank I, Tseng M, Tyagi SC. Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia, Am J Physiol Heart Circ Physiol 295: H890-H897, 2008.
36. Nakano E, Higgins JA, Powers HJ. Folate protects against oxidative modification of human LDL. Br J Nutr 86: 637-639, 2001.
37. Norton GR, Veliotes DGA, Osadchii O, Woodiwiss AJ, Thomas DP. Susceptibility to systolic dysfunction in the myocardium from chronically infarcted spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 294: H372-H378, 2008.
38. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protocols 3: 1422-1434, 2008.
39. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8: 221-233, 2007. (Pubitemid 46310551)
40. Pfeffer M, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81: 1161-1172, 1990.
41. Schuster E, Bulkley B. Expansion of transmural myocardial infarction: a pathophysiologic factor in cardiac rupture. Circulation 60: 1532-1538, 1979. (Pubitemid 10207884)
42. Sen U, Tyagi N, Patibandla PK, Dean WL, Tyagi SC, Roberts AM, Lominadze D. Fibrinogen-induced endothelin-1 production from endothelial cells. Am J Physiol Cell Physiol 296: C840-C847, 2009.
43. Sharpe CJ. Ventricular remodeling following myocardial infarction. Am J Cardiol 70: 20C-26C, 1992.
44. Song Y, Cook NR, Albert CM, Denburgh MV, Manson JE. Effect of Hcy-lowering treatment with folic acid and B vitamins on risk of type 2 diabetes in women, a randomized, controlled trial. Diabetes 58: 1921-1928, 2010.
45. Tummalapalli CM, Heath BJ, Tyagi SC. Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. J Cell Biochem 80: 512-521, 2001.
46. Tyagi N, Ovechkin AV, Lominadze D, Moshal KS, Tyagi SC. Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia. J Cell Biochem 98: 1150-1162, 2006. (Pubitemid 44131429)
47. Tyagi SC. Vasculogenesis and angiogenesis: extracellular matrix remodeling in coronary collateral arteries and the ischemic heart. J Cell Biochem 65: 388-394, 1997.
48. Tyagi SC, Meyer L, Schmaltz RA, Reddy HK, Voelker DJ. Proteinases and restenosis in the human coronary artery: extracellular matrix production exceeds the expression of proteolytic activity. Atherosclerosis 116: 43-57, 1995.
49. Verhaar MC, Wever RMF, Kastelein JJP, van Dam T, Koomans HA, Rabelink TJ. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 97: 237-241, 1998.
50. Warren SERH, Markis JE, Grossman W, McKay RG. Time course of left ventricular dilation after myocardial infarction: influence of infarct-related artery and success of coronary thrombolysis. J Am Coll Cardiol 11: 12-19, 1988. (Pubitemid 18029028)
51. Weisman H, Bush D, Mannisi J, Weisfeldt M, Healy B. Cellular mechanisms of myocardial infarct expansion. Circulation 78: 186-201, 1988.
52. Wilkinson IB, MacCallum H, Cockcroft JR, Webb DJ. Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. Br J Clin Pharmacol 53: 189-192, 2002. (Pubitemid 34264274)